Replies to post #23686 on BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

Or did it? They still never disclosed the CV benefits as per patent application,at least 71% CV risk reduction, and have switched focus of the patent which was granted Dec 25th, 2012 to lead with Testostrone replacement therapy of which HSDD is but one of the many uses.

Interestingly the modification to Lead the claim with Testosterone replacement therapy was Sept 7, 2011. Not a reaction to failed efficacy reported December 14, 2011.

A struggling Company would pull out the the stops to survive. Now the illusion of a struggling company will sit on information and play the Ace at an opportune time.

The blockbuster drug got bigger with the CV benefit discovery. Check out the other indication being tested in Clinical trials involving Restoring Testosterone (ie, Heart failure patients, osteoporosis etc..) The Abbott "Is it Low T? campaign.

I wonder if it is forced or planned?